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Invasive epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. The etiology of 
EOC remains elusive; however, experimental and epidemiologic data suggest a role for hormone-related 
exposures in ovarian carcinogenesis and risk factor differences by histologic phenotypes and 
developmental pathways. Research on pre-diagnosis androgen concentrations and EOC risk has yielded 
inconclusive results, and analyses incorporating EOC subtypes are sparse. We conducted a pooled 
analysis of 7 nested case-control studies in the Ovarian Cancer Cohort Consortium to investigate the 
association between pre-diagnosis circulating androgens (testosterone, free testosterone, 
androstenedione, dehydroepiandrosterone sulfate (DHEAS)), sex hormone binding globulin (SHBG), 
and EOC risk by tumor characteristics (i.e. histology, grade, and stage). The final study population 
included 1,331 EOC cases and 3,017 matched controls. Multivariable conditional logistic regression 
was used to assess risk associations in pooled individual data. Testosterone was positively associated 
with EOC risk (all subtypes combined, Odds Ratio (OR)log2=1.12 [95% Confidence Interval (CI) 1.02-
1.24]); other endogenous androgens and SHBG were not associated with overall risk. Higher 
concentrations of testosterone and androstenedione associated with an increased risk in endometrioid 
and mucinous tumors (e.g., testosterone, endometrioid tumors, ORlog2=1.40 [1.03-1.91]), but not serous 
or clear cell. An inverse association was observed between androstenedione and high grade serous 
tumors (ORlog2=0.76 [0.60-0.96]). Our analyses provide further evidence for a role of hormone-related 






Reproductive history influences risk of ovarian cancer and it has been hypothesized that these 
associations are mediated by exposure to endogenous hormones, including androgens (1). Data from 
experimental studies link androgen-related signalling to ovarian cancer through increased cellular 
proliferation and reduced apoptotic rates (2-4). The relationship between androgens and epithelial 
ovarian cancer (EOC) risk has been examined in 7 nested case-control studies with the numbers of cases 
in these studies ranging from 31 to 1,052 (5-10); these studies predominantly investigated EOC as a 
composite outcome. Emerging data show heterogeneity in risk factors by histologic subtypes (e.g., 
serous, endometrioid, mucinous, clear cell) and by the hypothesized “dualistic pathway” of ovarian 
carcinogenesis (defined by differences in the genetic make-up and the morphological architecture of 
histologic phenotypes) (11-18). The relationship between androgens and EOC risk by disease subtype 
has been minimally explored. Analyses to date suggest heterogeneity by subtype (9, 10); however, 
individual studies evaluating EOC by subtype were either limited by small case numbers in subtype 
analyses (9), or restricted to women pregnant at the time of serum sampling (10). 
We pooled and harmonized available data from 6 nested case-control studies within the Ovarian 
Cancer Cohort Consortium (OC3), plus the Finnish Maternity Cohort (FMC), to investigate the 
relationship of pre-diagnosis concentrations of androgens (e.g., testosterone, free testosterone, 
androstenedione, dehydroepiandrosterone-sulfate (DHEAS)) and sex-hormone binding globulin 
(SHBG) with EOC risk, overall and by subtype. Subtype analyses included analyses by histology, grade 
and stage, and by the hypothesized dualistic model of EOC development, i.e., type I vs. type II (19). Our 
study represents the largest investigation to date including individual-level data from 1,331 EOC cases 
and 3,017 matched controls, with 61 (clear cell) to 667 (serous) cases represented in the major histologic 
subtypes.  
Methods 
Study Population: Ovarian Cancer Cohort Consortium (OC3) 
The OC3 has been described previously (12). For this investigation, eligible cohorts were required to 
have data on a defined set of a priori selected covariates (e.g., menopausal status at blood donation, oral 




testosterone, androstenedione or DHEAS. In addition to the OC3 cohorts, the FMC, a cohort of women 
pregnant at blood collection, contributed data to this investigation (for contributing cohorts see 
Supplementary Table S1). Available biomarker and questionnaire data from each cohort were centrally 
collated and harmonized at the Data Coordinating Center at the Brigham and Women’s Hospital.  
Case characteristics  
Eligible cases included women diagnosed with invasive EOC (International Classification of Disease 
Codes (ICD): ICD9 codes 183 and 158; ICD10 code C56) ascertained by self-report with medical 
record confirmation and/or linkage to cancer registries. Cases were individually matched to two or three 
controls (free of cancer and alive at the time of diagnosis of the index case) on age, date, menopausal 
status and day or phase of menstrual cycle at blood collection in premenopausal women, with the 
exception of the FMC (matched on age and date at blood collection, parity at blood collection and at 
diagnosis/index date). Histomorphological data was complete, and the majority of cases had data on 
stage (82%); grade was available for 36% of the cases. We used histology and grade to classify tumors 
into type I ((48%, n=291); low-grade serous and endometrioid, all mucinous and clear cell) and type II 
((52%, n=314); high-grade serous, high-grade endometrioid) (19). Serous and endometrioid cases 
missing grade data were excluded from these analyses; mucinous and clear cell tumors were included 
regardless of grade data availability, as these tumors are classified as type I independent of grade. In a 
sensitivity analysis, all mucinous and clear cell cases missing grade were excluded from the type I 
subgroup (after exclusion, case n=77). The proportion of type I tumors was higher than expected; 
however, we observed the expected distribution (type I: 28% vs. type II: 72%) after excluding women 
from the FMC (all missing grade; younger at diagnosis and more frequently diagnosed with mucinous 
tumors than cases from the other cohorts).  
Laboratory methods 
In all studies, case-control sets were measured in the same batch and technicians performing the assays 
were blinded to case-control status and quality control samples. Information on sample type, laboratory 
assays, and intra- and inter-batch coefficients of variations for each cohort is summarized in 




testosterone and SHBG, with albumin assumed to be a constant 40g/L, according to the mass law of 
action (20). 
Statistical analyses 
Hormone measurements were standardized across studies based on the cohort-specific mean 
concentrations in controls (see supplemental methods; Supplemental Table S3). Conditional logistic 
regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). ORs were 
estimated using log2-transformed biomarker concentrations and study-specific tertiles based on the 
distribution in controls. A continuous probit score, generating a rank for each participant in each cohort 
by hormone concentration, was used to test for trend across tertiles. We additionally evaluated 
associations in quintiles for EOC overall and the serous subtype. Multivariable models included: parity 
[never, ever, missing (2.8%)] and OC use [never, ever, missing (47%); excluding FMC 2.3% missing]. 
Additional adjustment for body mass index (BMI; kg/m2) among women with data available (n=747 
cases), did not change the ORs (data not shown). 
Statistical analyses were conducted using a two-stage approach: First, ORs were calculated within each 
cohort and pooled using DerSimonian and Laird random effects meta-analysis models to assess 
between-study heterogeneity (21). Second, ORs were calculated based on pooled individual participant 
data (22). ORs estimated from meta-analysis and the data pooling method were similar, and we 
observed no significant between-study heterogeneity. Therefore, presented results are based on the 
pooled analysis. The assumption of linearity was tested using restricted cubic splines; no significant 
deviations from linearity were observed. Statistical heterogeneity of associations across subtypes was 
assessed via a likelihood ratio test comparing a model allowing the association for the risk factor of 
interest to vary by subtype versus one assuming the same association across subtype using polytomous 
conditional logistic regression (23).  
We evaluated associations after stratification by menopausal status at blood collection (premenopausal 
vs. postmenopausal) and age at diagnosis (<55 vs. ≥55 years). Androgen concentrations are relatively 
stable in pregnancy (24), however, we excluded FMC members in sensitivity analyses given that all 




analysis after exclusion of women diagnosed within two years after blood donation. A more detailed 
description of statistical procedures is available in the supplemental methods.  
SAS Statistical Software, version 9.3 (SAS Institute, Cary NC, USA) was used for statistical analyses. 
P-values<0.05 were considered as statistically significant; all statistical tests and p-values were two-
sided.  
Results 
In total 1,331 cases and 3,017 matched controls from 7 cohorts were included in this investigation 
(Table 1). Average age at blood collection ranged from 32 (FMC) to 61 years (CLUE II), and the 
majority of women were parous (89% cases, 94% controls) (Table 1). Average age at diagnosis ranged 
from 45 (FMC) to 67 (CLUE II) (Supplemental Table S4).  
Androgens and overall EOC risk 
A doubling of testosterone (i.e., 1-unit increase in log2-transformed testosterone) was associated with a 
12% increase in overall EOC risk (ORlog2=1.12; 95% Confidence Interval (CI) [1.02-1.24)], and a 25% 
increase in risk comparing top to bottom tertile (ORT3-T1=1.25 [1.06-1.48]; ptrend=0.03), Table 2). Free 
testosterone, androstenedione, DHEAS and SHBG were not associated with overall risk of EOC. 
Results from analyses evaluating quintiles of androgen and SHBG concentrations were similar to those 
from models using tertiles (Supplemental Table S5); however, the OR comparing highest vs. lowest 
quintile of testosterone was not statistically significant (ORQ5-Q1=1.22 [0.99-1.52]). 
Histologic subtypes  
The association between testosterone and EOC risk differed by histologic subtype (phet=0.06). Higher 
concentrations of circulating testosterone were associated with increased risk of endometrioid and 
mucinous tumors (e.g., endometrioid tumors: ORlog2=1.40 [1.03-1.91]), but not with serous or clear cell 
tumors (e.g., serous tumors: ORlog2=0.96 [0.84-1.11]). Free testosterone and androstenedione were 
associated with increased risk of mucinous tumors (e.g., androstenedione: ORlog2=1.33 [1.03-1.72], 




tumors: ORlog2=1.04 [0.76-1.43]). DHEAS and SHBG were not associated with any of the examined 
histologic subtypes. 
 
Tumor grade and developmental pathways 
We observed significant heterogeneity in the association between androstenedione and low grade EOC 
and high grade serous disease; androstenedione was significantly inversely associated with high grade 
serous EOC (phet=0.02; all low grade cases: ORlog2=1.41 [0.86-2.31]; high grade serous ORlog2=0.76 
[0.60-0.96]) (Table 3). The association between SHBG and EOC risk differed significantly by grade 
(phet=0.02); however, the individual effect estimates were not statistically significant. 
The association between androgens and EOC risk differed by developmental pathway (type I vs. type II 
tumors, phet, testosterone: 0.02; free testosterone: 0.01; androstenedione: <0.01; DHEAS: <0.01) (Figure 
1). Overall, higher concentrations of androgens were associated with increased risk of type I tumors, and 
reduced risk of type II tumors (e.g., androstenedione: type I: ORlog2=1.29 [1.05-1.60]; cases n=287; type 
II: ORlog2=0.74 [0.59-0.92], cases n=307; phet<0.01). Significant heterogeneity for androstenedione 
(p<0.01) and DHEAS (p=0.03) remained after exclusion of mucinous and clear cell cases missing data 
on grade from the type I subgroup (before exclusion, n=291 case-control sets; after exclusion, n=77 
case-control sets). However, while of the same general magnitude, the effect estimates were no longer 
statistically significant (Supplemental Figure S1).  
Sensitivity and Subgroup Analyses 
We observed some evidence of heterogeneity for the androgens and SHBG and overall EOC by 
menopausal status at blood collection (androstenedione, phet=0.05; SHBG, phet=0.02) and age at 
diagnosis (<55 years vs ≥55 years: androstenedione, phet=0.02; DHEAS, phet=0.05; SHBG, phet=0.05). 
Both androstenedione and SHBG were positively associated with risk only among women 
premenopausal at blood collection (androstenedione: premenopausal women, ORlog2=1.18 [1.03-1.35], 
postmenopausal women ORlog2=0.95 [0.82-1.12]; SHBG: premenopausal women, ORlog2=1.18 [1.00-




observed by menopausal status at blood collection. Androstenedione was associated with increased risk 
of EOC among women diagnosed before age 55 years, but not among women diagnosed at age 55 or 
older (<55 at diagnosis, ORlog2=1.21 [1.05-1.40], ≥55 years at diagnosis, ORlog2=0.95 [0.82-1.10]). 
While the association between DHEAS and SHBG and EOC differed by age at diagnosis, the ORs were 
not statistically significant in either age at diagnosis subgroup (e.g., SHBG, <55 at diagnosis, 
ORlog2=1.16 [0.98-1.38], ≥55 years at diagnosis, ORlog2=0.92 [0.79-1.07]). 
We observed no heterogeneity in analyses by stage at diagnosis. We observed an attenuation of the 
association between testosterone and EOC after excluding the FMC (n=576 cases, 43% of sample; after 
exclusion: ORlog2=1.06 [0.93 - 1.21]). Overall, ORs were similar for the histologic subtypes after this 
exclusion, however, no longer statistically significant (e.g., testosterone and endometrioid tumors, 
before exclusion: n=164, ORlog2=1.40 [1.03 - 1.91]; after exclusion: n=73, ORlog2=1.39 [0.81 - 2.36]. 
The most substantial attenuation was for the association between androstenedione and mucinous tumors 
(before exclusion: n=191 cases, ORlog2=1.33 [1.03 - 1.72]; after exclusion: n=49 cases, ORlog2=1.19 
[0.74 - 1.92]). Excluding women diagnosed within two years after blood donation did not meaningfully 
impact the results (data not shown). 
Discussion 
We investigated pre-diagnosis circulating concentrations of androgens and risk of EOC overall (n=1,331 
cases) and by subtype (case range, n=61 clear cell to 667 serous), in a collaborative re-analysis of 7 
nested case-control studies. The association between testosterone and risk of EOC differed by histologic 
subtype: endogenous androgens were predominantly associated with increased risk of endometrioid and 
mucinous tumors, while no significant associations were observed for serous or clear cell tumors, 
although some androgens were inversely associated with high-grade serous and endometrioid (Type II) 
disease.  
Ovarian cancer is comprised of four predominant histologic subtypes: serous, mucinous, endometrioid 
and clear cell. These histologic subtypes differ substantially by molecular alterations at diagnosis and 
presumed tissue of origin. The majority of serous tumors are high-grade neoplasms; this subtype 




high-grade serous EOC. It is hypothesized that a proportion of low-grade serous carcinomas develop 
from distal epithelium of the fallopian tube that implants on the ovarian surface epithelium (~ 80%), 
while high-grade serous tumors may arise from serous tubal intraepithelial carcinomas (STIC) within 
the fimbriated end of the fallopian tube (25, 26). Mucinous carcinomas are hypothesized to develop 
from the gastrointestinal mucosa or from transitional-type epithelium located at the tubal-peritoneal 
junction; borderline mucinous ovarian tumors are established precursors for this subtype (19). Both 
endometrioid and clear cell tumors have been proposed to arise from endometrial tissue, and have been 
associated with endometriosis and retrograde menstruation (19, 27).  
Beyond histologic subgroups, two hypothesized developmental pathways of tumorigenesis (type I and 
type II) have been defined using tumor molecular genetic characteristics (19, 25); in the absence of data 
on the tumor molecular profile, EOC is classified as type I or type II based on data on histology and 
grade. Type I tumors include low-grade serous, low-grade endometrioid, mucinous and malignant 
Brenner tumors (commonly present with KRAS, BRAF, PTEN, PIK3CA, CTNNB1, and ERBB2 
mutations)—subtypes that have been hypothesized to develop in a step-wise manner from borderline 
tumors or endometriosis within or on the surface of the ovary, and are typically diagnosed at earlier 
disease stage (27). Type II tumors include high-grade serous, high-grade endometrioid, malignant mixed 
and undifferentiated tumors (typically present with TP53 mutations, but none of the mutations observed 
in type I disease) (19). These latter tumors comprise the majority of EOCs, are aggressive, and typically 
present at an advanced stage.  
Prior epidemiologic data suggest risk factor differences by EOC subtype defined by histology (e.g. (12, 
15-18)) and developmental pathway (11, 14). Consistent differences by histologic subtype of invasive 
EOC are observed for hormone-related risk factors including duration of OC use (lower risk of all 
histologic subtypes but mucinous; (12, 15)), older age at menopause (higher risk of all but mucinous; 
(12)), smoking (higher risk of mucinous, lower risk of clear cell; (12, 17)), parity (more strongly 
protective in non-serous subtypes; (12)), postmenopausal hormone therapy (HT) use (higher risk of 
serous and endometrioid subtypes only; (12, 18)), and adiposity (among non-HT users; higher risk of 




consistently show stronger associations between parity and type I, relative to type II, disease (11, 14). 
Three prospective studies evaluated circulating estrogens (10, 28) and/or androgens (9, 10) and invasive 
EOC risk by subtype. Higher concentrations of both estrogens and androgens were associated with 
increased risk of non-serous EOC subtypes (9, 10, 28), whereas higher concentrations of 
androstenedione had opposing effects on risk of type I (higher risk) and type II (lower risk) EOC (9). 
In women, androgens are produced in the ovary, adrenal glands, and via peripheral conversion of 
androgen precursors (e.g., DHEA); in turn, androgens are the substrate for estrogen production by 
aromatase. DHEAS is a pre-androgen synthesized in the adrenal gland, and subsequently metabolized 
toward androstenedione and testosterone, or estradiol (29). Androstenedione, an intermediate between 
DHEA and DHEAS and testosterone, is produced in both the ovary (premenopausal women: 40%; 
postmenopausal women: 20-30%) and the adrenal gland. In premenopausal women, approximately 25% 
of circulating testosterone originates in the ovary, 25% in the adrenal glands, and 50% is metabolized 
from precursors such as androstenedione in peripheral tissues (e.g., liver, adipose tissue) (29, 30); the 
proportion of testosterone of ovarian origin is higher in postmenopausal women (~50%) (29). These 
androgens are correlated with each other (e.g., r=0.54 between DHEAS and androstenedione to r=0.69 
between DHEAS and testosterone; adjusted for menopausal status (6)) and weakly correlated with 
estradiol (e.g., estradiol and testosterone: premenopausal women: r=0.08 (31);  postmenopausal women, 
r=0.23-0.38; (32, 33)) and body mass index (r=0.07-0.13; (31-33)).   
Androgens may (1) directly influence ovarian carcinogenesis through androgen receptor (AR) signaling, 
or (2) impact risk through their role as estrogen precursors; associations with estrogens may be most 
evident in the context of progesterone insufficiency as observed in polycystic ovarian syndrome 
(PCOS). ARs and estrogen (ER) receptors are expressed in the normal ovary, including ovarian surface 
epithelial cells and cortical inclusion cysts, and the fallopian tube (34-36). In vivo data show that ovarian 
cancer preferentially develops in a hormonal milieu enriched with androgens (e.g., testosterone induces 
epithelial neoplasms in guinea pigs (37)) or estrogens (e.g., estrogen-induced tumor growth in high-
grade serous ovarian cancers) (38, 39). The hyperandrogenic PCOS is characterized by functional 




to 45% of cases additionally present with adrenal hyperandrogenism (41). Estimates of PCOS 
prevalence range from 5 to 15% (30); the syndrome has highest prevalence among reproductive-age 
women. PCOS-related androgen excess is observed in both pre- and postmenopausal women (42). 
Progesterone deficiency is a hallmark of PCOS, resulting in a higher ratio of estrogens to progesterone. 
PCOS (43, 44) and relatively high levels of estrogens unopposed by progesterone are associated with 
increased endometrial cancer risk (i.e., estrogen-alone HT (45), relatively high endogenous estrogens in 
postmenopausal women (33, 46)). These associations with endometrial cancer may be most relevant to 
the endometrioid or clear cell EOC, given endometrial tissue is a proposed tissue of origin for these 
subtypes. PCOS itself has not consistently been associated with ovarian cancer (43, 44, 47), though data 
by subtype are limited. Data to date suggest both estrogen-alone and estrogen plus progesterone HT are 
associated with increased risk of endometrioid EOC (18).  
In the current study, we evaluated three members of the androgen synthesis pathway—DHEAS, 
androstenedione, testosterone—and EOC risk by histology (i.e., accounting for hypothesized differences 
in cell of origin) and developmental pathway (i.e., “less” relative to “more” aggressive disease). We 
observed a significant positive association between testosterone and risk of endometrioid ovarian 
cancer. There is limited in vitro evidence to support a role of androgens in the etiology of endometrioid 
EOC (34, 48). However, given the possible common tissue of origin, it is plausible that androgens 
impact risk similarly in both endometrial cancer and endometrioid EOC. With respect to endometrial 
cancer, recent in vivo data have demonstrated that androgens induce epithelial proliferation in the mouse 
uterus (49), and epidemiologic data provide some support for an association between androgens and 
endometrial cancer risk (50). Together, this data on endometrial cancer provides indirect evidence 
supporting an association between androgens and endometrioid EOC. Androgens are an intermediate on 
the estrogen-synthesis pathway, and estrogen exposure unopposed by progesterone may be the 
underlying biological mechanism linking androgens to endometrioid EOC, particularly if in the context 
progesterone deficiency, as in PCOS and in postmenopausal women. Prior research has linked higher 
early pregnancy estradiol concentrations to a 2.5-fold increase in risk of endometrioid EOC (10), and 
postmenopausal HT use (12, 18) and adiposity (16) are associated with increased risk of this subtype. 




(2) adipose tissue is a key site of metabolism of androgens to estrogens in postmenopausal women. 
Adjustment for BMI did not impact the results. Data on history of PCOS were not available.  
Higher concentrations of all investigated androgens, except DHEAS, were significantly associated with 
increased risk of mucinous tumors. Emerging data suggest the ovarian stroma proximal to mucinous 
EOC has higher concentrations of sex-steroid producing enzymes than distant stroma, providing support 
for a role for sex steroids in the development of mucinous disease (35). Androgens (directly, or after 
conversion to estrogens) may contribute to growth promotion in the early stages of mucinous disease; 
however, to our knowledge, the androgen responsiveness of mucinous tumors is not well characterized, 
and data on ER expression are limited (51, 52). The precise biological mechanisms underlying the 
observed associations between androgens and mucinous tumors remain an open question.  
In line with two prior prospective studies (9, 10), both included in this analysis, we observed no 
association with pre-diagnosis androgen concentrations and increased risk of serous carcinomas. Recent 
data on estrogens and ovarian cancer are in line with our results on androgens, with no association 
observed between estrogens and risk of invasive serous tumors in the FMC (first-trimester estrogens) 
(10) or among postmenopausal women in the Women’s Health Initiative (28). We observed no 
associations with clear cell disease. However, sample size for this subtype was limited. 
We observed significant heterogeneity in the strength of associations between androgens and risk of 
type I vs. type II tumors; higher androgen concentrations were associated with higher risk of type I, but 
lower risk of type II (predominantly high grade serous), tumors. These results are in agreement with the 
single prior study on endogenous androgens and EOC risk using the dualistic model classification (9); 
these data from the European Prospective Investigation into Cancer and Nutrition (EPIC) were included 
in the current analysis. There is indirect evidence for differences in hormone dependency in type I and 
type II tumors, based on the variation of ER expression between low-grade (ER expression: 58%) and 
high-grade serous carcinomas (ER expression: 27%) (53). However, the mechanisms linking androgen 
concentrations to lower risk of type II tumors in our study are unclear. While chance and residual 
confounding may explain the results, future work should explicitly examine the impact of androgens on 




Given the large sample size, our study was powered to investigate risk associations for less common 
tumors (e.g., mucinous tumors) and by developmental pathway (type I/type II). A general weakness of 
pooled analyses is the difference in data availability of covariates and differences in laboratory methods. 
In this investigation, data from each cohort were centrally compiled and harmonized and we addressed 
differences in absolute biomarker concentrations (I) using study-specific tertiles and (II) standardizing 
hormone measurements using study-specific mean concentrations. Results were robust regardless of 
whether we calculated ORs from the pooling of individual data or from meta-analysis. For some of the 
investigated hormones the number of sets that could be used was reduced for subgroup analyses, which 
resulted in reduced power. In our primary analyses using the developmental pathway classification, we 
included all mucinous and clear cell tumors in the “type I” classification, as their classification is 
independent of grade. If there were systematic differences in the observed associations with type I 
disease in cases with and without grade data, this may result in a biased interpretation of the differences 
between type I and type II EOC. However, the associations observed in our primary analysis and in a 
sensitivity analysis restricted to women with complete data on grade were of similar magnitude. Many 
statistical tests are reported; therefore some significant observations may be due to chance. However, all 
statistical analyses were hypothesis driven. In line with the majority of other epidemiological studies, a 
single measurement of biomarkers was used to assess risk associations. This single measurement may 
not reflect long-term average concentrations and the storage time and conditions may impact the true 
value of the biochemical indicators. However, the stability of androgen measurements over time has 
been shown previously for a period over at least 2-3 years: (1) premenopausal women [ICC ranged from 
0.58 (androstenedione) up to 0.81 (DHEAS), (54) and (2) postmenopausal women [ICC ranged from 
0.66 (androstenedione) up to 0.92 (SHBG) (55).  
The testosterone synthesis pathway (e.g., DHEAS, androstenedione, testosterone) may play an 
important role in the onset and progression of a subset of epithelial invasive ovarian carcinomas. 
Androgens may either have a direct impact on ovarian carcinogenesis, or act through increased 
synthesis of other steroid hormones (e.g., estrogens); this is an area for future epidemiologic research. 
While androgens were associated with increased risk of non-serous tumors, we observed an inverse 




findings on hormone-related pathways in ovarian carcinogenesis, this study supports emerging data on 
the heterogeneity of epithelial invasive ovarian cancer and underscores the importance of examining 
etiologic differences for subtypes.  
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Table 1. Case and control characteristics in pooled analysis of prospective data on circulating androgens, SHBG and EOC risk: the Ovarian Cancer Cohort Consortium (OC3) 











Clue II ≠ Case 46 60.8 (13.0) 19% 20% 85% 26.3 (5.8) 
 ≠ Control 91 61.0 (12.9) 13% 13% 86% 25.4 (4.6) 
EPIC Ose et al. 2014 Case 451 55.9 (8.5) 18% 37% 77% 26.8 (4.9) 
  Control 867 55.9 (8.6) 12% 45% 77% 26.3 (4.7) 
FMC Schock et al. 2014 Case 576 32.5 (4.8) 0% ≠≠ 0% ≠≠ 
  Control 1,433 32.5 (4.7) 0% ≠≠ 0% ≠≠ 
NHS Tworoger et al. 2007 Case 117 57.7 (6.5) 8% 41% 79% 24.8 (4.8) 
  Control 348 57.7 (6.5) 5% 47% 79% 24.7 (4.1) 
NHS II Tworoger et al. 2007 Case 15 46.1 (4.4) 20% 93% 20% 29.6 (9.8) 
  Control 44 45.8 (4.3) 23% 86% 18% 25.9 (5.8) 
NYUWHS Lukanova et al. 2002 Case 63 52.6 (8.6) 47% 29% 56% 24.5 (3.8) 
  Control 112 52.0 (8.5) 38% 36% 54% 25.9 (4.3) 
WHS Tworoger et al. 2007 Case 63 55.7 (7.2) 25% 65% 75% 24.5 (3.9) 
  Control 122 55.5 (7.0) 15% 71% 70% 25.1 (4.4) 
Total  Case 1,331 45.8 (13.7) 11% 40% 42% 26.2 (5.1) 
  Control 3,017 44.8 (13.7) 6% 47% 39% 25.8 (4.6) 
1Among women with data: parity 2.8% missing; OC use 47% missing (excluding FMC: 2.3% missing) 
2At blood collection 
 BMI = body mass index; OC = oral contraceptive; OC3 = Ovarian Cancer Cohort Consortium; SHBG = sex hormone binding globulin; SD = standard deviation; CLUE = Washington County, MD Study ‘Give us a clue to 
cancer and heart disease’; EPIC = European Prospective Investigation into Cancer and Nutrition; FMC = Finnish Maternity Cohort; NHS = Nurses’ Health Study; NYUWHS = New York University Women’s Health Study; 
WHS = Women’s Health Study. 
 ≠      Data from Clue II have not been published.  





Table 2: Odds ratios (95% CI) for EOC overall and by histologic subtypes in tertiles and for doubling of androgen concentrations: the Ovarian Cancer Cohort Consortium (OC3)1  
          Invasive  EOC                 Serous            Endometrioid            Mucinous          Clear Cell 
                          Sets            OR (95%CI)        ptrend Sets OR (95%CI) ptrend Sets OR (95%CI)         ptrend Sets OR (95%CI)         ptrend Sets   OR (95%CI)          ptrend 
Testosterone               
T1     398 ref  222 ref    35 ref   45 ref  15 ref  
T2    443 1.20 (1.02 - 1.41)  229 1.16 (0.92 - 1.46)    60 1.46 (0.88 - 2.42)   61 1.34 (0.86 - 2.08)  27 1.65 (0.73 - 3.73)  
T32    460 1.25 (1.06 - 1.48) 0.03 204 0.97 (0.76 - 1.24) 0.56   69 1.80 (1.08 - 3.01) 0.06  84 1.94 (1.25 - 3.02) 0.05 17 0.82 (0.34 - 2.00) 0.68 
Doubling3 1,301 1.12 (1.02 - 1.24) 0.02 655 0.96 (0.84 - 1.11) 0.61 164 1.40 (1.03 - 1.91) 0.03 190 1.29 (1.01 - 1.66) 0.04 59 1.12 (0.69 - 1.80) 0.65 
phet4               0.06 
Free Testosterone               
T1     286 ref  155 ref  25 ref   35 ref  11 ref  
T2    287 1.05 (0.85 - 1.28)  151 1.04 (0.79 - 1.38)  32 0.94 (0.48 - 1.86)   48 1.46 (0.85 - 2.52)  10 0.82 (0.27 - 2.48)  
T32    292 1.06 (0.87 - 1.31) 0.04 129 0.83 (0.62 - 1.10) 0.63 36 1.03 (0.53 - 1.99) 0.45  50 1.50 (0.88 - 2.54) 0.03 20 2.02 (0.67 - 6.12) 0.26 
Doubling3    865 1.10 (1.00 - 1.21) 0.05 435 0.97 (0.84 - 1.11) 0.61 93 1.11 (0.80 - 1.53) 0.53 133 1.33 (1.04 - 1.72) 0.03 41 1.32 (0.82 - 2.11) 0.26 
phet4               0.12 
Androstenedione               
T1     450 ref  235 ref   46 ref   56 ref  21 ref  
T2    387 0.86 (0.73 - 1.02)  204 0.88 (0.70 - 1.12)   45 0.67 (0.4 - 1.13)   51 0.90 (0.57 - 1.42)  15 0.93 (0.41 - 2.10)  
T32    470 1.07 (0.90 - 1.28) 0.13 217 0.99 (0.77 - 1.28) 0.79  73 0.99 (0.59 - 1.67) 0.82  84 1.57 (1.01 - 2.42) 0.03 24 0.81 (0.37 - 1.77) 0.62 
Doubling3 1,307 1.08 (0.97 - 1.19) 0.16 656 0.97 (0.84 - 1.12) 0.69 164 1.04 (0.76 - 1.43) 0.82 191 1.33 (1.03 - 1.72) 0.03 60 1.07 (0.69 - 1.66) 0.77 
phet4               0.17 
DHEAS               
T1     227 ref  128 ref  18 ref    8 ref    7 ref  
T2    245 1.08 (0.86 - 1.36)  127 1.06 (0.77 - 1.45)  23 0.81 (0.36 - 1.82)  16 1.04 (0.35 - 3.08)  12 3.36 (0.88 - 12.8)  
T32    219 0.95 (0.74 - 1.23) 0.87 111 0.83 (0.59 - 1.18) 0.45 28 1.02 (0.42 - 2.47) 0.85 20 1.53 (0.50 - 4.71) 0.29 14 3.50 (1.03 - 11.9) 0.10 
Doubling3    691 0.99 (0.89 - 1.10) 0.82 366 0.93 (0.81 - 1.08) 0.36 69 1.05 (0.72 - 1.53) 0.78 44 1.34 (0.81 - 2.23) 0.26 33 1.52 (0.87 - 2.65) 0.14 
phet4               0.22 
SHBG               
T1     311 ref  147 ref  30 ref   56 ref  19 ref  
T2    250 0.82 (0.67 - 1.00)  141 0.89 (0.67 - 1.18)  27 0.98 (0.49 - 1.93)   28 0.61 (0.36 - 1.05)  12 0.75 (0.30 - 1.91)  
T32    325 1.09 (0.89 - 1.33) 0.56 157 1.14 (0.86 - 1.52) 0.39 37 1.49 (0.78 - 2.85) 0.44  51 0.96 (0.58 - 1.57) 0.79 12 0.75 (0.29 - 1.97) 0.50 
Doubling3    886 1.02 (0.91 - 1.14) 0.76 445 1.06 (0.91 - 1.25) 0.43 94 1.16 (0.80 - 1.67) 0.43 135 0.93 (0.68 - 1.28) 0.65 43 0.77 (0.46 - 1.30) 0.33 
phet4               0.43 
1Results were derived from conditional logistic regression models, additionally adjusted for OC use (never/ever/missing) and parity (never/ever/missing); 2The p value for trend across tertiles is based on a continuous probit score 
(generating a rank for each person in each cohort by hormone level); 3Linear trends for doubling of hormone concentrations were estimated on log2 scale; 4 Pair-wise heterogeneity tests were performed, using the likelihood ratio test 
comparing models assuming (1) the same association between exposure and outcomes compared to (2) a model assuming different associations for each subtype. 




Table 3: Odds ratios (95% CI) for EOC for 
doubling of androgen concentrations and 
stratified by grade at diagnosis overall and 
for serous tumors: the Ovarian Cancer 
Cohort Consortium (OC3) 1 
 Sets OR (95%CI) 
Testosterone   
Low grade   55 1.28 (0.80 – 2.07) 
High grade   
          All  407 0.94 (0.79 - 1.12) 
          Serous  260 0.84 (0.67 - 1.04) 
 phet2 0.25 
 phet3 0.12 
Free Testosterone   
Low grade   38 1.34 (0.79 - 2.27) 
High grade   
         All  277 0.95 (0.80 - 1.13) 
    Serous 180 0.92 (0.74 - 1.13) 
 phet2 0.24 
 phet3 0.19 
Androstenedione   
Low grade   55 1.41 (0.86 - 2.31) 
High grade   
         All  406 0.84 (0.69 - 1.01) 
    Serous 259 0.76 (0.60 - 0.96) 
 phet2 0.05 
 phet3 0.02 
DHEAS   
Low grade   49 1.32 (0.89 - 1.97) 
High grade   
         All  374 0.93 (0.81 - 1.07) 
    Serous 234 0.91 (0.76 - 1.08) 
 phet2 0.07 
 phet3 0.06 
SHBG   
Low grade   38 0.59 (0.33 - 1.03) 
High grade   
         All  286 1.12 (0.93 - 1.36) 
    Serous 185 1.17 (0.92 - 1.49) 
 phet2 0.02 
 phet3 0.02 
1Results were derived from conditional logistic regression models, additionally adjusted for OC use (never/ever/missing) and parity 
(never/ever/missing). Pair-wise heterogeneity tests were performed, using the likelihood ratio test comparing models assuming (1) the same 
association between exposure and outcomes compared to (2) a model assuming different associations for each subtype. 2Comparing all high 








Figure 1.  
Title: Odds ratios (95% CI) for EOC for doubling of androgen concentrations and EOC risk by the 
Type I and Type II classification: the Ovarian Cancer Cohort Consortium (OC3). 
 
 
Results were derived from conditional logistic regression models, additionally adjusted for OC use 
(never/ever/missing) and parity (never/ever/missing). Pair-wise heterogeneity tests were performed, 
using the likelihood ratio test comparing models assuming (1) the same association between exposure 
and outcomes compared to (2) a model assuming different associations for each subtype. 






Online-Only Supplemental Material 
Study population and methods 
The study population was based on the following cohorts: the ‘Washington Country, MD 
Study ‘Give us a clue to cancer and heart disease’ (CLUE) II, European Prospective 
Investigation into Cancer and Nutrition (EPIC), the Finnish Maternity Cohort (FMC), the 
Nurses’ Health Study (NHS), NHS II, the Harvard Women’s Health Study (WHS) and the 
New York University Women’s Health Study (NYUWHS) (Table S1). In all cohorts, cases 
were individually matched to two (CLUE II, EPIC, NYUWHS, WHS) or up to three controls 
(FMC, NHS, NHS II) on age, date (or follow-up time in EPIC), menopausal status at blood 
collection and day or phase of menstrual cycle in premenopausal women (with exception of 
the FMC, which was restricted to currently pregnant women).  
Selection of case patients and control participants 
EOC cases in the participating cohorts are ascertained by (1) self-report with subsequent 
medical record confirmation (2) and/or linkage to cancer registries that in each study 
generally is estimated to be >95% complete. Analyses were limited to women diagnosed with 
invasive ovarian carcinomas and with data on histologic subtype.  
Data on tumor characteristics 
The OC3 database contained complete information on histomorphology: 50% of tumors were 
of serous histology (n=667), 15% mucinous (n=193), 12% endometrioid (n=166), 5% clear 
cell (n=61) and 18% other (malignant epithelial neoplasms, carcinoma, malignant mixed 
Müllerian or malignant Brenner tumors; n=244). Information on tumor stage was 82% 
complete and cases with local disease were classified as low stage (23%), whereas cases with 
regional or metastatic disease were classified as high stage (77%). Data on grade were 
provided by CLUE II, EPIC, NHS, NHS II, WHS and NYUWHS, and were available for 36% 




poorly/undifferentiated tumors as high grade (88%). In the absence of data on molecular 
genetics and immunohistochemistry, information on histology and grade can be used to 
classify tumors as put forward by Kurman and colleagues [1].  
Assessment of reproductive factors and lifestyle characteristics 
Data on reproductive and lifestyle characteristics at blood collection were collected from 
participating cohorts. Available data from each cohort were sent to the coordinating center at 
the Brigham and Women’s Hospital for centralized harmonization. Information was requested 
for (1) general data (e.g., ID, matched Case-Set ID, matching variables, sample types and 
laboratory batches), (2) lifestyle related data (e.g., BMI, smoking status) and (3) reproductive 
and hormone-related data (e.g., parity, menopausal status at blood collection, phase of 
menstrual cycle in premenopausal women, OC or postmenopausal hormone therapy (HT) 
use).  
To account for potential interference of exogenous hormones with circulating concentrations 
[2], women using OC or HT at the time of blood collection were either: (1) excluded a priori 
(e.g., EPIC, NHS II premenopausal) or (2) cases and controls were matched on HT use at 
blood donation (e.g., CLUE II, NHS, NHS II postmenopausal or WHS). It was presumed that 
FMC participants (pregnant at blood collection) were not using exogenous hormones at the 
time of blood donation. 
Laboratory methods 
All participating studies used a nested case-control design, with assays arranged so that case-
control sets were measured in the same batch and technicians performing the assays were 
blinded to case-control status and quality control samples. Hormone concentrations were 
measured in serum in EPIC (except Sweden), FMC and the NYUWHS; heparin plasma 
specimens were used in CLUEII and the NHS and NHS II; and EDTA plasma was used for 




intra- and interbatch coefficients, are presented in Table S2. Free testosterone was calculated 
for CLUE II, EPIC, FMC and NYUWHS, based on measured concentrations of testosterone 
and SHBG, with albumin assumed to be a constant 40g/L, according to the mass law of action 
[3]. 
Statistical analyses 
Outliers were identified and removed using the ESD approach [4]. As biomarker data 
deviated from the normal distribution, we applied the log2 transformation to limit 
heteroscedasticity. To account for differences in study-specific mean concentrations and a 
slightly different case-control ratio between studies (1:2 vs. 1:3), data were standardized 
based on the cohort-specific mean concentrations in controls (Table S3). 
Statistical analyses were conducted using a two-stage approach (I) using random effect meta- 
analyses and (II) an aggregated data approach based on individual participant data. First, the 
log2 relative risks were calculated from conditional logistic regression models within each 
cohort and pooled using DerSimonian and Laird random effects models (random effects 
pooling, [5]). Heterogeneity between cohort-specific effect estimates was tested by 
DerSimonian and Lairds Q statistic [5] and conducted for all analyses (invasive EOC, by 
histologic subtype, stage, grade, type I / type II model, menopausal status at blood donation, 
age at diagnosis and exclusion of women diagnosed within 2 years after blood donation). 
NHS, NHS II and WHS data were combined for meta-analysis, as these studies were 
evaluated together in a previous publication [6], and specimens were analyzed in the same 
laboratory. Based on the relatively small case numbers in some cohorts (e.g., CLUE II: cases 
n=46) meta-analyses were performed in the crude model (accounting for matching factors), 




Second, in the aggregated approach, individual participant data from all cohorts were pooled 
and a combined effect estimate was calculated from a conditional logistic regression model 
[7]. The original matched sets were retained for all statistical analyses. 
Data analysis was conducted using the Unix SAS system to access data remotely on the 
external servers at the study coordinating center at Brigham and Women’s Hospital (SAS 
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considered as statistically significant; all statistical tests and corresponding p-values were 
two-sided. Forest plots were prepared using the R software (package ‘rmeta’, function 
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Table S1: Basic information on the participating cohort studies for the pooled analysis on androgens and EOC: the Ovarian Cancer Cohort Consortium (OC3) 
Cohort (cases)     Population        Recruitment         
                                                            period 
 Fasting  
  status 
Storage   Matching criteria 
    Controls  
per case 
Age at blood 
donation 












-70°C 1:2 ± 1 years ± 14 days ± 1 day Menopausal 
status at blood 
collection 
Current OC / HT 
use 








1992-2000 Matched -196°C1 1:2 ± 6 months No (incidence 
density 
sampling) 
5 phases Menopausal 
status at blood 
collection  
Recruitment 
center, Time of the 
day of blood 
collection,  





-25°C 1:3 ± 6 months ± 3 months Not 
applicable 
Not available Parity (1,2,>2), 
parity at diagnosis 
(1,2,>2) 
NHS and II2 
(138) 
Registered 
nurses in the 
USA 







Time of day, use 
of postmenopausal 
hormones at blood 
collection  















randomization (± 6 
months), 
NYUWHS (63) Women 
attending breast 
cancer screening 
center, NY USA 
1985-91 Non-
fasting 




status at blood 
donation 
Number of blood 
donations 
CLUE II = Washington County, MD Study ‘Give us a clue to cancer and heart disease’. EPIC= European Prospective Investigation into Cancer and Nutrition. FMC= Finnish Maternity Cohort. NHS= Nurses’ Health Study. 
NYU WHS = New York University Women’s Health Study. 1Most samples were stored in liquid nitrogen at -196°C, apart from Denmark and Sweden were samples were stored locally at -150°C and -70°C. 2NHS phase 1 





Table S2: Laboratory assays and Intra- and Inter-batch CVs for the participating cohorts: the Ovarian Cancer 
Cohort Consortium (OC3) 







   CLUE II heparin plasma direct RIA 12.9 22.2 





   EPIC phase 2 12.7 7.6 
   FMC serum HPLC tandem mass spec. 9.7 8.1 
   NHS heparin plasma liquid chromatography/mass spec.  
13.3* 
- 
   NHS II - 
   WHS EDTA plasma Liquid chromatography/mass spec. - 
   NYUWHS serum Direct RIA1 9.6 14 
DHEAS 
   CLUE II heparin plasma direct RIA < 3 <10 
   EPIC phase 1 serum 
 
direct RIA1 3.4 11.6 
   EPIC phase 2 direct RIA1 8.2 6.2 
   FMC - - - - 
   NHS heparin plasma 
heparin plasma 
chemiluminescent immunoassay  
3.8* 
- 
   NHS II chemiluminescent immunoassay - 
   WHS EDTA plasma chemiluminescent immunoassay - 
   NYUWHS serum direct RIA1 4.6 11.5 
Androstenedione 
   CLUE II heparin plasma double-antibody RIA 8.6 10.0 
   EPIC phase 1 serum 
 
direct RIA3 3.0 8.4 
   EPIC phase 2 direct RIA3 20.5 10.4 
   FMC serum HPLC tandem mass spectrometry 8.3 7.7 
   NHS heparin plasma Liquid chromatography/mass spec.  
9.4* 
- 
   NHS II Liquid chromatography/mass spec. - 
   WHS EDTA plasma Liquid chromatography/mass spec. - 
   NYUWHS serum double-antibody RIA3 7.0 13.8 
SHBG 
   CLUE II heparin plasma direct “sandwich” immunoradiometric 1.4 22.2 
   EPIC phase 1 serum direct “sandwich” immunoradiometric5 
direct “sandwich” immunoradiometric5 
4.2 10.7 
   EPIC phase 2 serum 5.9 3.2 
   FMC serum chemiluminescence 8.7 3.7 
   NHS  - - - - 
   NHS II - - - - 
   WHS - - - - 
   NYUWHS serum direct ‘sandwich’immunoradiometric5 6.2 11.5 
1Radio-Immuno-Assay (RIA) Immunotech, Marseille, France; 2Beckman Coulter, Brea, California; 3Diagnostic System Laboratories (DSL),  
Webster, Texas, USA; 4Beckman and Coulter, Brea, California, USA; 5CIS-Bio, Gif-sur-Yvette, France; 6Enzyme-linked  
immunosorbent assay (ELISA); DSL, Webster, Texas, USA; 7Immunodiagnostics Systems, Germany. *average intra-batch coefficient from 






Table S3. Geometric means of hormone concentrations (95% CI) by cohort and case-control status after log2 transformation and standardization: the Ovarian Cancer Cohort 
Consortium (OC3) 




DHEAS (ug/dl) SHBG (nmol/l) 
Clue II Cases      46 1.10 (0.96-1.27) 1.11 (0.92-1.32) 1.10 (0.95-1.28) 1.01 (0.83-1.23) 1.04 (0.90-1.22) 
 Controls       91 1.00 (0.90-1.11) 1.00 (0.88-1.13) 1.00 (0.90-1.11) 1.00 (0.87-1.15) 1.00 (0.90-1.11) 
EPIC Cases    451 1.00 (0.96-1.05) 1.04 (0.98-1.10) 0.98 (0.94-1.03) 1.03 (0.97-1.10) 0.97 (0.92-1.02) 
 Controls     867 1.00 (0.97-1.03) 1.00 (0.96-1.04) 1.00 (0.97-1.04) 1.00 (0.96-1.05) 1.00 (0.97-1.03) 
FMC Cases    576 1.07 (1.03-1.11) 1.07 (1.00-1.14) 1.07 (1.03-1.12) ≠≠ 1.04 (0.98-1.10) 
 Controls  1,433 1.00 (0.97-1.03) 1.00 (0.96-1.04) 1.00 (0.97-1.03) ≠≠ 1.00 (0.90-1.11) 
NHS Cases    117 1.05 (0.96-1.15) ≠≠ 0.93 (0.84-1.02) 0.87 (0.77-0.99) ≠≠ 
 Controls     348 1.00 (0.95-1.05) ≠≠ 1.00 (0.94-1.06) 1.00 (0.93-1.07) ≠≠ 
NHS II Cases      15 1.17 (0.91-1.50) ≠≠ 1.03 (0.79-1.36) 0.94 (0.67-1.34) ≠≠ 
 Controls       45 1.00 (0.86-1.16) ≠≠ 1.00 (0.85-1.18) 1.00 (0.82-1.22) ≠≠ 
NYU WHS Cases      63 0.98 (0.87-1.11) 0.92 (0.79-1.08) 0.95 (0.84-1.09) ≠≠ 1.08 (0.95-1.23) 
 Controls     112 1.00 (0.91-1.10) 1.00 (0.89-1.12) 1.00 (0.91-1.10) ≠≠ 1.00 (0.91-1.10) 
WHS Cases      63 0.90 (0.80-1.02) ≠≠ 1.01 (0.88-1.15) 1.00 (0.85-1.19) ≠≠ 






Table S4. Tumor characteristics in pooled analysis of prospective data on circulating androgens, SHBG and EOC risk: the Ovarian Cancer Cohort Consortium (OC3) 
 Clue II EPIC FMC NHS NHS II NYUWHS WHS Total 
References ≠ Ose et al. 2014 Schock et al. 2014 Tworoger et al. 
2008 
Tworoger et al. 
2008 
Lukanova et al. 
2002 
Tworoger et al. 
2008 
 
No 46 451 576 117 15 63 63 1,331 
Age at dx, yrs 1 67.4 (13.0) 62.5 (8.9) 44.7 (8.1) 65.0 (7.3) 48.8 (3.8) 59.8 (8.8) 60.1 (8.0) 54.8 (12.4) 
Lag time, yrs 1 6.6 (3.0) 6.6 (3.6) 12.3 (6.8) 7.3 (4.0) 2.7 (1.9) 7.2 (3.5) 4.3 (2.6) 9.0 (6.0) 
Histology         
Serous 19 (41%) 238 (53%) 263 (46%) 62 (53%) 5 (33%) 38 (60%) 42 (67%) 667 (50%) 
Endometrioid 5 (11%) 45 (10%) 92 (16%) 11 (9%) 4 (27%) 4 (6%) 5 (8%) 166 (12%) 
Mucinous 2 (4%) 30 (7%) 143 (25%) 9 (8%) 1 (7%) 6 (10%) 2 (3%) 193 (15%) 
Clear cell 2 (4%) 25 (6%) 23 (4%) 4 (3%) 2 (13%) 5 (8%) - 61 (5%) 
Others 18 (39%) 113 (25%) 55 (10%) 31 (27%) 3 (20%) 10 (16%) 14 (22%) 244 (18%) 
Grade 2         
Low grade 1 (4%) 31 (12%) - 11 (12%) 3 (25%) 7 (14%) 3 (7%) 56 (12%) 
High grade 24 (96%) 220 (88%) - 79 (88%) 9 (75%) 43 (86%) 42 (93%) 417 (88%) 
Stage 2         
Low stage 3 (9%) 57 (14%) 150 (31%) 27 (23%) 7 (47%) 13 (24%) - 257 (23%) 
High stage 29 (91%) 341 (86%) 332 (69%) 88 (77%) 8 (53%) 41 (76%) - 839 (77%) 
Type 2         
Type I 5 (24%) 76 (32%) 166 20 (24%) 6 (55%) 14 (30%) 4 (11%) 291 (48%) 
Type II 16 (76%) 163 (68%) - 65 (76%) 5 (45%) 33 (70%) 32 (89%) 314 (52%) 
1presented as mean (SD)  
2Among cases with data. grade missing for 64%, stage missing for 18%, Type I/II missing for 55%  






Table S5. Odds ratios (95% CI) for invasive EOC overall and the serous subtype in quintiles of androgen 
and SHBG concentrations: OC31 
 Invasive EOC  Serous EOC 
 Sets OR (95% CI) ptrend2  Sets OR (95% CI) ptrend2 
Testosterone 
Q1 254 ref   145 ref  
Q2 250 1.00 (0.81-1.23)   128 0.88 (0.66-1.18)  
Q3 251 1.10 (0.89-1.36)   140 1.13 (0.84-1.50)  
Q4 267 1.12 (0.90-1.38)   121 0.88 (0.65-1.19)  
Q5 279 1.22 (0.99-1.52) 0.03  121 0.88 (0.65-1.20) 0.56 
Free Testosterone 
Q1 159 ref   84 ref  
Q2 179 1.08 (0.83-1.41)   96 1.04 (0.72-1.49)  
Q3 177 1.15 (0.87-1.50)   90 1.10 (0.76-1.60)  
Q4 149 0.97 (0.73-1.28)   85 0.95 (0.65-1.38)  
Q5 201 1.29 (0.99-1.68) 0.04  80 0.88 (0.60-1.29) 0.63 
Androstenedione 
Q1 260 ref   138 ref  
Q2 265 1.07 (0.87-1.33)   141 1.02 (0.76-1.37)  
Q3 220 0.88 (0.70-1.10)   114 0.77 (0.57-1.06)  
Q4 276 1.10 (0.89-1.37)   145 1.14 (0.74-1.54)  
Q5 286 1.20 (0.95-1.51) 0.13  118 0.90 (0.64-1.25) 0.79 
DHEAS 
Q1 135 ref   74 ref  
Q2 133 0.97 (0.73-1.31)   74 1.01 (0.68-1.50)  
Q3 158 1.18 (0.88-1.58)   78 1.22 (0.81-1.82)  
Q4 116 0.88 (0.64-1.20)   66 0.93 (0.61-1.41)  
Q5 149 1.13 (0.82-1.55) 0.87  74 0.99 (0.63-1.54) 0.45 
SHBG 
Q1 186 ref   85 ref  
Q2 183 0.99 (0.77-1.28)   96 1.18 (0.83-1.69)  
Q3 137 0.77 (0.59-1.00)   76 0.89 (0.62-1.28)  
Q4 180 0.99 (0.76-1.27)   92 1.05 (0.73-1.50)  
Q5 200 1.14 (0.88-1.48) 0.56  96 1.31 (0.90-1.89) 0.39 
1Results were derived from conditional logistic regression models, additionally adjusted for OC use (never/ever/missing) and parity 
(never/ever/missing); 2The p value for trend across quintiles is based on a continuous probit score (generating a rank for each person in 








Figure S1. Odds ratios (95% CI) for doubling of androgen concentrations and Type I EOC restricted 
to cases with data on tumor grade (phet comparing type I and type II: testosterone, 0.09; free 
testosterone, 0.38; androstenedione, <0.01; DHEAS, 0.03; SHBG, 0.14; type II ORs shown in Figure 
1): the Ovarian Cancer Cohort Consortium (OC3) 
	
 
Results were derived from conditional logistic regression models, additionally adjusted for OC use 
(never/ever/missing) and parity (never/ever/missing). Pair-wise heterogeneity tests were performed, 
using the likelihood ratio test comparing models assuming (1) the same association between exposure 
and outcomes compared to (2) a model assuming different associations for each subtype. 
DHEAS=dehydroepiandrosterone sulfate; SHBG=sex hormone binding globulin 
	
 
